Navigation Links
Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
Date:9/11/2007

ses which would confound the data

-- not be on other medications which would confound the data

-- not so advanced in their neuropathy that they are not capable of

improvement

Although the Company believes enrollment should be completed before year end 2007, based on the protocol and stringent criteria submitted to the FDA, it is difficult to predict exactly when the study will be completed.

Currently in the United States, there are approximately 20,000,000 people with Diabetes. Of this population, nearly one half have or will have the symptoms of Peripheral Neuropathy. The company believes that a safe and effective topical product approved by the FDA as a "first line" treatment for diabetic peripheral neuropathy could develop a significant market position in a growing therapeutic category currently dominated by systemic therapies.

The Quigley Corporation makes no representation that the US Food and Drug Administration or any other regulatory agency will allow this Investigational New Drug to be marketed. Furthermore, no claim is made that potential medicine discussed herein is safe, effective, or approved by the Food and Drug Administration. Additionally, data that demonstrates activity or effectiveness in animals or in vitro tests do not necessarily mean the formula test compound; referenced herein will be effective in humans. Safety and effectiveness in humans will have to be demonstrated by means of adequate and well-controlled clinical studies before the clinical significance of the formula test compound is known. Readers should carefully review the risk factors described in filings the Company files from time to time with the Securities and Exchange Commission.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer
'/>"/>

SOURCE The Quigley Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Merge eMed releases software upgrade
11. Sony releases tool for Blu-ray disc production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Ireland , September 18, 2014 ... and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has ... "Biocompatible Materials - Global Strategic Business ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes ... in US$ Million by the following ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... the "Global N-acetylcysteine Industry Report 2014" ... Global N-acetylcysteine Industry Report 2014 is a professional ... the global N-acetylcysteine industry. The report ... definitions, classifications, applications and industry chain structure. The ...
(Date:9/18/2014)... LOUIS , Sept. 18, 2014  U.S. biotech ... by signing an exclusive license for technology developed by ... control gene expression in plants, including for applications in ... The technology was developed under the ... officer at Kultevat and former president of the Danforth ...
(Date:9/18/2014)... septembre 2014 Mapi, société créée à ... a été depuis 40 ans l,un des ... traditionnelles par des évaluations recentrées sur le ... impacts économiques des traitements. Logo ... A cours d,une récente conférence téléphonique avec ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 21974 - 2014 - Mapi fĂȘte ses 40 ans 2
... August 24 Health Robotics today reported,that on ... McKesson, it,has received categorical support from virtually all ... few days since the partnership was publicly announced.,While ... on industry events, a few reactions to the ...
... , , , NEW YORK, Aug. ... the pre-disease collection, processing and long-term storage of adult stem cells for ... Technology Company with the New York Department of Taxation and Finance, for ... The Company has notified certain shareholders that, as a result of this ...
... OSLO, August 24 PCI Biotech Holding ... delivery of cancer therapeutics,today announced that the first ... with the lead candidate Amphinex(R), which uses a ... at the,University College Hospital (UCH) in London. PCI,s ...
Cached Biology Technology:Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership 2Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership 3Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership 4NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20% 2NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20% 3PCI Biotech Commences Phase I/II Trials of Amphinex(R) 2
(Date:9/18/2014)... 2014Many Americans across racial and ethnic groups describe ... on their day-to-day life, more so than other ... speech (57% of African-Americans, 49% of non-Hispanic whites, ... asked which disease or ailment is the worst ... among African-Americans followed by AIDS/HIV. Hispanics and ...
(Date:9/18/2014)... carbon and nitrogen comprise all spheres of our ... have caused imbalances and perturbations that resulted in ... GHGs result in climate changes which influence the ... the atmosphere. Understanding these feedback mechanisms has become ... science during the past three decades. , In ...
(Date:9/18/2014)... is probably the ultimate form of camouflage: you don,t ... this strategy is not as uncommon as you might ... County, USA, explains that the larval life stages of ... part of the anatomy that most creatures cannot make ... have to shield each individual eye unit with an ...
Breaking Biology News(10 mins):Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Greenhouse gas research enters a new era 2Transparent larvae hide opaque eyes behind reflections 2
... ROCKVILLE, MD, USA/BEIJING, CHINA -- The global fight against ... and the China National Biotec Group (CNBG) announce that ... tuberculosis (TB) vaccines. The agreement between the leading non-profit ... corporation in China signals a commitment by both to ...
... Barbara, Calif.) When UC Santa Barbara geochemist David Valentine ... bacteria blooms had consumed almost all of the deepwater methane ... people were skeptical. How, they asked, could almost all of ... disappear? In a new study published in the ...
... location and the political instability in the region have kept ... , But Hyongki Lee, a University of Houston civil engineering ... this mysterious region _ studying it from space. , Lee ... He plans to use unanalyzed satellite images to survey the ...
Cached Biology News:Aeras and CNBG sign agreement on tuberculosis vaccine R&D 2UCSB scientists say topography played key role in Deepwater Horizon disaster 2UCSB scientists say topography played key role in Deepwater Horizon disaster 3UCSB scientists say topography played key role in Deepwater Horizon disaster 4University of Houston wins NASA grant to study Congo River Basin 2
Mouse anti-hepatitis delta virus Class: Antibody Product Group: Bacterial and Viral Antigen...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
Biology Products: